Ascend Integrative Medicine
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
Los Angeles, CA
Los Angeles sits at the center of a large Southern California regenerative market: orthopedic and sports-medicine practices offering orthobiologics, cash-pay longevity clinics, medspas that market “stem cell” facials, and academic centers running regulated trials. That breadth creates noise for patients comparing stem cell therapy in Los Angeles, California. Similar labels can hide very different cell sources, processing steps, and oversight.
This hub lists clinics that appear in our Directory for this city and treatment. Inclusion is not an endorsement, and listing order is not a paid ranking. Regenerated.com is free for patients. Organic relevance and published evidence signals are separate from any labeled Featured or Sponsored placement. Verified badges, when present, reflect credential checks (not spend).
When you evaluate Los Angeles stem cell options, ask what tissue or cell source is used, whether the protocol is same-day or culture-expanded, who performs the procedure, what outcomes are measured, and how adverse events are handled. Local marketing often borrows research language. Interest in a mechanism is not the same as a proven disease-modifying therapy for your condition.
Prefer clinicians who can explain risks in plain language, document informed consent, and connect claims to published evidence grades rather than testimonials alone. Before you trust badges or counts on this page, read How to read a Regenerated city hub and Featured vs Verified vs organic. Then return here for Los Angeles listings.
Regulatory context
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.
Available here
Nationwide
Stem Cell Therapy clinics across the US